Premium
Does cost‐effectiveness play a role in clinical trials?
Author(s) -
Steele Tace,
Pawaskar Manjiri,
Balkrishnan Rajesh,
Fleischer Alan,
Feldman Steven R.
Publication year - 2007
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/j.1529-8019.2007.00119.x
Subject(s) - medicine , clinical trial , indirect costs , productivity , cost driver , atopic dermatitis , intervention (counseling) , cost effectiveness , marketing , nursing , risk analysis (engineering) , dermatology , business , pathology , accounting , economics , macroeconomics
Cost is a measure of resources consumed. By assessing costs, pharmacoeconomic studies complement studies of efficacy and safety, helping to determine the relationships of treatment and outcome. Costs are divided into three categories, including direct cost (resources attributable to the intervention), indirect cost (resulting from reduced productivity), and intangible cost (incurred from pain and emotional suffering). Insurance companies, patients, doctors, and the society all have different perspectives with respect to costs. The present authors review different types of cost analyses and their use in studies of psoriasis, atopic dermatitis, and basal cell carcinoma treatment. Cost studies influence clinicians, policy makers, and third‐party payers’ decisions regarding the implementation of particular therapies or programs. Collection of cost data needs to be incorporated into clinical trials to facilitate these decisions.